A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This is a randomized, blinded, placebo-controlled, multicenter, Phase II study designed to
provide a preliminary assessment of the safety and efficacy of combining bevacizumab with
bortezomib in patients with relapsed or refractory multiple myeloma.